Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.295 EUR | +7.92% | +15.11% | -1.15% |
01:50pm | ITALY GROWTH WINNERS & LOSERS: Erfo and iVision Tech lead the risers | AN |
Mar. 29 | Laboratorio Farmaceutico Erfo, revenues grow and profit remains stable | AN |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Capitalization 1 | 18.27 | 10.8 | 10.8 | - |
Enterprise Value (EV) 1 | 17.27 | 9.2 | 8.8 | 8.3 |
P/E ratio | - | 13.3 x | 20 x | 17.1 x |
Yield | - | - | - | - |
Capitalization / Revenue | 3.63 x | 1.71 x | 1.66 x | 1.46 x |
EV / Revenue | 3.43 x | 1.46 x | 1.35 x | 1.12 x |
EV / EBITDA | 9.58 x | 5.11 x | 5.5 x | 4.61 x |
EV / FCF | -41.5 x | 9.2 x | 9.78 x | 7.55 x |
FCF Yield | -2.41% | 10.9% | 10.2% | 13.3% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 9,000 | 9,000 | 9,000 | - |
Reference price 2 | 2.030 | 1.200 | 1.200 | 1.200 |
Announcement Date | 3/31/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | 5.104 | 5.028 | 6.3 | 6.5 | 7.4 |
EBITDA 1 | - | 1.804 | 1.8 | 1.6 | 1.8 |
EBIT 1 | - | 1.17 | 1.1 | 0.8 | 0.9 |
Operating Margin | - | 23.26% | 17.46% | 12.31% | 12.16% |
Earnings before Tax (EBT) 1 | - | 0.9485 | 1.1 | 0.8 | 0.9 |
Net income 1 | 1.158 | 0.7161 | 0.8 | 0.6 | 0.7 |
Net margin | 22.68% | 14.24% | 12.7% | 9.23% | 9.46% |
EPS 2 | - | - | 0.0900 | 0.0600 | 0.0700 |
Free Cash Flow 1 | - | -0.4161 | 1 | 0.9 | 1.1 |
FCF margin | - | -8.27% | 15.87% | 13.85% | 14.86% |
FCF Conversion (EBITDA) | - | - | 55.56% | 56.25% | 61.11% |
FCF Conversion (Net income) | - | - | 125% | 150% | 157.14% |
Dividend per Share | - | - | - | - | - |
Announcement Date | 4/5/22 | 3/31/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | 1 | 1.6 | 2 | 2.5 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -0.42 | 1 | 0.9 | 1.1 |
ROE (net income / shareholders' equity) | - | 11.4% | 10.2% | 7.1% | 8.4% |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 1.18 | 1.5 | 0.6 | 0.6 |
Capex / Sales | - | 23.42% | 23.81% | 9.23% | 8.11% |
Announcement Date | 4/5/22 | 3/31/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-1.15% | 11.68M | |
+31.59% | 588B | |
-3.20% | 364B | |
+19.55% | 326B | |
+5.14% | 285B | |
+15.55% | 239B | |
+10.18% | 210B | |
-7.16% | 200B | |
+9.01% | 167B | |
-0.47% | 161B |
- Stock Market
- Equities
- ERFO Stock
- Financials Laboratorio Farmaceutico Erfo S.p.A.